548 Episodo

  1. Choosing the Right Viral Vector for a Gene Therapy

    Publicado: 1/4/2021
  2. A Software Platform to Give Patients the Tools to Build Treatments for Rare Genetic Diseases

    Publicado: 25/3/2021
  3. Side Effects: The Toll a Rare Disease Can Take on a Family in Pursuit of a Cure

    Publicado: 19/3/2021
  4. Realizing the Potential of CRISPR Gene Editing

    Publicado: 12/3/2021
  5. Understanding the Economic Toll of Rare Disease in the United States

    Publicado: 4/3/2021
  6. The Promise of Gene-Based Therapies for Neurodegenerative Conditions

    Publicado: 25/2/2021
  7. Moving Beyond Viral Vectors for Gene Therapies

    Publicado: 19/2/2021
  8. Acquisitions Help Jazz Build Toward Commercial Crescendo

    Publicado: 12/2/2021
  9. Powerful Gene Editing Approach Offers the Promise of Correcting a Range of Rare Diseases

    Publicado: 5/2/2021
  10. A Child's-Eye-View of Clinical Trials

    Publicado: 29/1/2021
  11. Using Nanoliposomes to Make Cancer Therapies Safer and More Effective

    Publicado: 21/1/2021
  12. Accelerating Treatments for Rare Disease through Data Sharing

    Publicado: 14/1/2021
  13. Treating the Root Cause of Sickle Cell Disease

    Publicado: 8/1/2021
  14. Targeting a Common Pathway in Genetic Forms of Obesity

    Publicado: 30/12/2020
  15. After Pruning Orchard, Gaspar Focuses on High Value Opportunities

    Publicado: 23/12/2020
  16. Writing a New Chapter of Genetic Medicine

    Publicado: 17/12/2020
  17. How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment

    Publicado: 10/12/2020
  18. With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

    Publicado: 4/12/2020
  19. Making Gene Therapies Accessible to Patient with Ultra-Rare Conditions

    Publicado: 26/11/2020
  20. Using RNA Therapies to Target Inherited Retinal Diseases

    Publicado: 20/11/2020

12 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site